Bixiye
QP63-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Ryplazim® (plasminogen, human-tvmh)
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Natiijooyinka Raadinta
Soo bandhiga 1721 - 1730 ee natiijooyinka 3688
Bixiye
P44-22 New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective October 3, 2022
Taariikhda barnaamijka Dhaqangalayso Agosto 01, 2022
Bixiye
P45-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Taariikhda barnaamijka Dhaqangalayso Agosto 01, 2022
Bixiye
QP61-22 Free Continuing Education for Mental Health Providers through 12/31/22
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Bixiye
QP47-22 Medical Drug Management Update – Alpha-1 Proteinase Inhibitors
Taariikhda wax ku ool ah ee barnaamijka: Jun 08, 2022
Bixiye
QP48-22 MHCP Pharmacy Benefit Exclusion for Korsuva™ and Leqvio®
Taariikhda wax ku ool ah ee barnaamijka: Jun 08, 2022
Bixiye
QP49-22 Commercial Pharmacy Benefit Exclusion for Carvykti™, Korsuva™, and Leqvio®
Taariikhda wax ku ool ah ee barnaamijka: Jun 08, 2022
Bixiye
QP50-22 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective August 1, 2022
Taariikhda wax ku ool ah ee barnaamijka: Jun 08, 2022
Bixiye
P42-22 Mental Health and Substance Use Disorder Provider Survey
Taariikhda dhaqangalka Barnaamijka: Jul 01, 2022